The size of the North America Infectious Disease Therapeutics Market is estimated to grow USD 62.83 billion by 2027 from USD 43.08 billion in 2022, growing at a CAGR of 7.84% during the forecast period.
The increased prevalence of infectious diseases, rising funding for research and development, and rising awareness initiatives by different government and non-profit organizations contribute to the expansion of the infectious disease therapeutics market in North America. Various disease prevention programs are also being implemented across the world. Furthermore, the government, private sector, and nonprofit groups are all working to improve illness management. As a result, all of these factors are projected to contribute to market expansion. The high prevalence of malaria and other infections, the rising incidence of these disorders, and rising expenditure on preventing and detecting infectious diseases are anticipated to drive this market's expansion.
The worldwide incidence of infectious illnesses and the start of COVID-19 and increased awareness for early disease detection, a change in focus from centralized laboratories to decentralized POC testing, and technical developments are driving market expansion. In addition, the market is projected to expand due to a favorable reimbursement scenario that covers the diagnosis and treatment of various diseases. The factors driving the growth of this market are likely to be the rising prevalence of infectious diseases, rising expenditure to boost the penetration rate of treatments for these diseases, rising initiatives to raise awareness about treatments and diagnosis of these conditions, and increasing clinical trial studies for the development of new drugs. Due to the rising prevalence of infectious diseases, increased awareness of the early diagnosis of infectious diseases, and increased research funding activities by various private and government organizations, the infectious disease therapeutics market is expected to grow significantly over the forecast period.
Inadequate reimbursement is a key major obstacle to the infectious disease diagnostics market expansion. As a result, most diagnostic businesses confront a significant challenge in commercializing their tests: getting health insurance to pay for them. In addition, the global infectious diseases therapeutics industry may face a challenge when patents on infectious illness medicines expire.
This research report on the North America Infectious Disease Therapeutics Market has been segmented & sub-segmented into the following categories:
By Mode of Treatment:
By Target Organism:
By Infection type:
By Distribution Channels:
Geographically, because of the growing incidence of infectious diseases and the availability of better healthcare infrastructure, the United States is anticipated to be the largest infectious disease therapeutic market. In the United States, the rate of antibiotic prescriptions is rather high. Furthermore, the trend varies substantially depending on the provider in a given state. In addition, there is an increasing prevalence of HIV in the United States and an increase in approvals for new disease treatments, all of which are projected to drive market growth. The rising number of prescriptions for infectious illness diagnostic tests is due to the diagnosis and management of such disorders. During the forecast period, these factors, together with the rising movement toward preventative care, are likely to boost demand for infectious disease diagnostics.
KEY MARKET PLAYERS:
A few of the key companies operating in the North America Infectious Disease Therapeutics Market profiled in this report are F. Hoffmann-La Roche, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, Merck & Co, Pfizer, Achillion Pharmaceuticals, Novartis, AbbVie, Astellas Pharma, AstraZeneca, Auritec Pharmaceuticals, Bayer, Bristol-Myers Squibb, Chimerix Pharmaceuticals, Cubist, Eli Lilly, Isis Pharmaceuticals, Mitsubishi Tanabe Pharma, pSivida and Sanofi.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: firstname.lastname@example.org